Erhalte mehr Antworten von Arbeitgebern
Versende in nur wenigen Minuten einen passgenauen Lebenslauf.
The University of Basel invites applications for a fully funded Postdoctoral position in AI-driven drug design within the Computational Pharmacy group. The project aims to combine generative AI, large synthetic spaces, physics-informed representations, and experimental feedback in closed-loop DMTA cycles.
The successful candidate will develop and validate computational AI methods, collaborate with international industrial partners, and contribute to publications and project reporting.
University of Basel ranks among the world’s one hundred best universities and boast a top‑ten place among German‑speaking universities.
Artificial intelligence is rapidly transforming molecular design and drug discovery. However, the identification of successful drug candidates requires more than generating molecules with high predicted affinity: selectivity, physicochemical properties, potential adverse effects, synthetic accessibility, and experimental feedback must be considered simultaneously.
Our research in the Computational Pharmacy group at the University of Basel focuses on developing next‑generation AI approaches for drug design by combining state‑of‑the‑art machine learning with physicochemical knowledge and molecular modeling.
Representative publications from our group include:
https://doi.org/10.1038/s41467-025-63947-5
https://doi.org/10.1021/acs.jcim.2c01436
https://doi.org/10.1021/acs.jcim.1c01438
https://doi.org/10.1038/s42004-020-0261-x
A fully funded Postdoctoral position is available in the Computational Pharmacy group at the University of Basel within an international Innosuisse research project on AI-driven closed-loop drug discovery.
The project aims to establish an integrated Design-Make-Test (DMTA) platform combining generative AI, ultra‑large synthetically accessible chemical spaces, physics‑informed molecular representations, off‑target prediction, and experimental feedback. The developed methods will be applied in iterative prospective drug‑discovery cycles, with a serine protease from the complement system serving as a real‑world lead‑optimization case study.
The successful candidate will play a central role in the computational and AI components of the project and work closely with our international and industrial project partners.
The position is available immediately.
You can find out more about our research at: https://pharma.unibas.ch/de/research/research-groups/computational-pharmacy-2155/
For questions, please contact Prof. Markus Lill ( marcus.lill@example.com ).